ESALF - FDA OKs Merck/Eisai's Keytruda + Lenvima combo in endometrial cancer

Merck (MRK) announces that the FDA has approved the combination of Keytruda, plus Eisai's (ESALF) Lenvima for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.The approval is based on results from the Phase 3 KEYNOTE-775/Study 309 trial, in which Keytruda plus Lenvima demonstrated statistically significant improvements in overall survival, progression-free survival, and overall response versus chemotherapy (investigator’s choice of doxorubicin or paclitaxel).

For further details see:

FDA OKs Merck/Eisai's Keytruda + Lenvima combo in endometrial cancer